Vatche Agopian
P-28: Purification And Digital Scoring Of Extracellular Vesicles For Detection Of Early-Stage Hepatocellular Carcinoma
Giuliana Amaddeo
O-15: A Multicenter, Cross-Section Study Of The Impact Of Covid-19 Pandemic On The Management Of Hepatocellular Carcinoma A High-Prevalence French Area.
Jesper B. Andersen
Associate Professor and Group leader
University of Copenhagen · Biotech Research and Innovation Centre (BRIC)


Stephen Chan
Associate Professor
Department of Clinical Oncology, The Chinese University of Hong Kong
Ann-Lii Cheng
Director, NTU Cancer Center
National Taiwan University Cancer Center
Josep Corominas Argente del Castillo
P-86: Activated Peripheral Blood Lypmphocytes Of Hepatocellular Carcinoma Patients (Hcc) Are Associated With Increased Risk Of Early Dermatologic Adverse Effects During Sorafenib Treatment
Amanda Craig
P-92: Characterization Of Chromatin Accessibility In Hepatocellular Carcinoma Cells Using Single Cell Atac Sequencing


Helena Degroote
O-01: International, multicenter study on the outcome of locoregional therapy before liver transplant for hepatocellular carcinoma extending the Milan criteria
Maria Die Trill
Coordinator of the Psycho-Oncology Unit of the Hospital Universitario Gregorio Marañón and Assistant Professor at the School of Psychology, Universidad Complutense of Madrid, Spain
Liangqing Dong
P-70: Immunogenomic Characterization Of Multifocal Liver Cancer


Anthony El-Khoueiry
Associate Professor of Clinical Medicine;Norris Cancer Center CISO
Anthony B. El-Khoueiry
0-24: Outcomes For Patients With Advanced Hepatocellular Carcinoma And Child-Pugh B Liver Function In The Phase 3 Celestial Study Of Cabozantinib Versus Placebo


Sandrine Faivre
Professor of Medical Oncology at the University Paris VII
Petros Fessas
P-109: Post-Registration Experience Of Nivolumab Therapy In Patients With Advanced Hepatocellular Carcinoma (Hcc): An International Study.
Richard Finn
Professor of Clinical Medicine Division of Hematology/ Oncology UCLA David Geffen School of Medicine University of California, Los Angeles
Richard Finn
P-03: Ramucirumab For Patients With Advanced Hepatocellular Carcinoma And Elevated Alpha Fetoprotein Following A Non-Sorafenib Based Systemic Therapy: Interim Results From An Expansion Cohort Of The Phase 3 Reach-2 Study
Sarah Fritzsche
P-90: Implications Of Notch3 Expression And Signaling For Cholangiocarcinogenesis
Geoffrey Fucile
O-06: Supervised Learning Based On Tumor Imaging And Biopsy-Derived Transcriptomic Data Predicts Response Of Hepatocellular Carcinoma To Transarterial


Nathalie Ganne-Carrié
P-66: Overall Survival Is Impacted By Liver Failure And Co-Morbidities Rather Than Etiology Of Cirrhosis In Patients With Hepatocellular Carcinoma Detected During A Surveillance Program
Gregory Gores
Executive Dean for Research, Physician Scientist
Mayo Clinic


Saur Hajiev
O-02: Impact Of Age On Sorafenib Outcomes In Hepatocellular Carcinoma: An International Cohort Study.
Matthew Holzner
O-14: Is Repeat Resection For Recurrent Intrahepatic Cholangiocarcinoma Warranted? Outcomes Of An International Multicenter Analysis


Hyo-Jin Kang
O-03: Prospective Intra-Individual Comparison Of Contrast-Enhanced Ultrasound With Sulfur Hexafluoride And Perfluorobutane For Diagnosis Of Hepatocellular
R. Katie Kelley
O-22: The Novel Regimen Of Tremelimumab In Combination With Durvalumab Provides A Favorable Safety Profile And Clinical Activity For Patients With Advanced
R.Kate Kelley
Associate Professor of Clinical Medicine in the Department of Medicine at the University of California, San Francisco (UCSF) and the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC).
Laura Kulik
Hepatology & Liver Transplantation Professor, Medicine, Northwestern University Medical School, Chicago


Riccardo Lencioni
Director of the Division of Diagnostic Imaging and Intervention in the Department of Hepatology and Liver Transplantation at Pisa University Hospital in Italy
Monika Lewinska
O-05: Lysyl Oxidase Shapes Physical And Metabolic Interactions Between Tumor And Stroma In Cholangiocarcinoma Patients
Lijuan Liu
P-32: Standardized Sampling And Reporting Protocol Is The Key To Improve Microvascular Invasion Detection Rate
Josep Maria Llovet
Emilien Loeuillard
P-91: Dual Targeting Of Tumor Associated Macrophages And Immunosuppressive Granulocytic Myeloid-Derived Suppressor Cells Augments Pd-1 Blockade In Cholangiocarcinoma
Amaia Lujambio
Ph.D. Assistant Professor
Icahn School of Medicine at Mount Sinai
Amaia Lujambio Goizueta
O-08: Cooperation Between Distinct Cancer Driver Genes Underlies Inter-Tumor Heterogeneity In Hepatocellular Carcinoma


Anand Mehta
P-40: A Fucosylated Kininogen-Based Biomarker Panel Is Highly Accurate For Early Detection Hepatocellular Carcinoma In Patients With Cirrhosis: A Phase Iii Biomarker Evaluation
Neil Mehta
O-23: Transarterial Chemoembolization And Radioembolization Are Similarly Effective In Achieving Successful Hepatocellular Carcinoma Downstaging In The Multicenter Evaluation Of Reduction In Tumor Size Before Liver Transplantation (Merits-Lt) Consortium
Philippe Merle
P-115: Sequential Treatment With Sorafenib Followed By Regorafenib In Patients With Unresectable Hepatocellular Carcinoma (HCC): Interim Analysis Of The Observational REFINE Study
Tim Meyer
Professor of Experimental Cancer Medicine at UCL and Honorary Consultant in Medical Oncology at the Royal Free and ULCH Hospitals. ILCA Communication Committee Chair.


Pierre Nahon
0-25: Radiological And Pathological Response To Neoadjuvant Nivolumab In Patients With Bclc A Hcc Treated By Curative Percutaneous Irreversible Electroporation: Preliminary Report From The French Multicentre Phase 2 Nivolep Trial.
Jean Charles Nault
Associated professor in Liver unit, Jean Verdier Hospital, Bondy, France. ILCA Communications Committee Chair.
Massih Ningarhari
O-07: Telomere Length Is A Major Determinant Of Hepatocellular Carcinoma Diversity And A Therapeutic Target


Joong-Won Park
O-26: Proton Beam Radiotherapy Versus Radiofrequency Ablation Treatment In Patients With Recurrent Hepatocellular Carcinoma: A Randomized Controlled Phase 3 Non-Inferiority Aproh Trial
David J. Pinato
Clinical Senior Lecturer in Medical Oncology
Imperial College London
Federico Piñero
O-12: The Metroticket 2.0 And Afp Score Have Similar Performance To Predict Post-Lt Outcomes: Results Of A Multinational Multicentre Cohort Study.


Maria Reig
Hepatic Oncology (BCLC)
Hospital Clinic - Barcelona
David Repáraz
P-81: Cold-Inducible Rna Binding Protein As A Vaccination Platform Against Hepatocellular Carcinoma
Lorenza Rimassa
Deputy Director Medical Oncology Unit Humanitas Cancer Center Humanitas Research Hospital - IRCCS, Milan, Italy
Sasan Roayaie
MD, FACS. General Surgery (board-certified)
Giulia Rovesti
O-09: Prognostic Role Of Pecs2 Index In Advanced Biliary Tract Cancer Patients Treated With First Line Chemotherapy: Training And Validation Cohorts.


Bruno Sangro
Director of the Liver Unit and Co-Director of the HPB Oncology Area at Clínica Universidad de Navarra in Pamplona, Spain. ILCA President (2019 - 2021)
Bruno Sangro
P-103: Exposure-Response Analysis For Nivolumab + Ipilimumab Combination Therapy In Patients With Advanced Hepatocellular Carcinoma
Bruno Sangro.
O:27: Nivolumab After Selective Internal Radiation Therapy (Sirt) Using Sir-Spheres Resin Microspheres In Patients With Hepatocellular Carcinoma: The Nasir-Hcc Trial
Morris Sherman
Professor of Medicine at University of Toronto. ILCA Past President
Daniela Sia
Assistant Professor in the Division of Liver Diseases, Department of Medicine, at Icahn School of Medicine at Mount Sinai (ISMMS)
Amit Singal
Associate Professor at UT Southwestern Medical Center
Amit Singal
O-20: Improved Sensitivity For Early-Stage Hepatocellular Carcinoma Detection With A Novel Blood-Based Panel Of Methylated Dna And Protein Markers
Amit G. Singal
O-13: Patient-Reported Barriers Are Associated With Hcc Surveillance Receipt In A Multi-Center Cohort Of Patients With Cirrhosis
Amit G.. Singal
P-47: Benefits And Harms Of Hepatocellular Carcinoma Surveillance In A Prospective Cohort Of Patients With Cirrhosis
Won Sohn
P-56: Abnormal And Euthyroid Ranges Of Thyroid Hormones In Serum And Liver Cancer Mortality: A Cohort Study
Florian Strasser
Head of Integrated Oncological Rehabilitation at Klinik Gais AG, Switzerland, and Senior Consultant Clinic for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, Switzerland.


Dr. Parissa Tabrizian
O-10: Early Recurrence Of Hepatocellular Carcinoma Following Transplantation: Risk Score From A Multi-Institutional Study Of > 3000 Patients
Laura Torrens
P-76: Immune-Remodeling Effects Of Lenvatinib Plus Anti-Pd1 In A Murine Model Of Hepatocellular Carcinoma


Enric Vercher Herraez
P-77: Identification Of Neoantigen-Reactive Tumor-Infiltrating T Cell In Hepatocellular Carcinoma.
Eric Vibert
Academic surgeon at AP-HP specialized in the liver surgery and transplantation at Paul Brousse Hospital, Villejuif, France
Augusto Villanueva
Assistant Professor in the Liver Cancer Program (Icahn School of Medicine at Mount Sinai, New York). ILCA Executive Secretary.
Johann von Felden
O-19: Unannotated Small RNA In Circulating Extracellular Vesicles Detect Early Stage Liver Cancer


Catherine Willoughby
O-04: Cabozantinib Enhances The Efficacy And Immune Activity Of Anti-Pd1 Therapy In A Murine Model Of Hepatocellular Carcinoma


Han Xiao
O-16: Construction And Implementation Of An Artificial Intelligence Model For Microvascular Invasion Prediction Of Hepatocellular Carcinoma


Takeshi Yokoo
O-17: Comparative Accuracy Of Abbreviated Mri Vs. Ultrasound For Detection Of Early-Stage Hcc In Patients With Cirrhosis


Xuehong Zhang
O-21: Inflammatory And Insulinemic Potential Of Diet And Lifestyle With Risk Of Hepatocellular Carcinoma
Andrew Zhu
Director of Jiahui International Cancer Center, Director Emeritus of Liver Cancer Research at Massachusetts General Hospital Cancer Center, and Professor of Medicine at Harvard Medical School
Andrew X. Zhu
0-18: Alpha-Fetoprotein (AFP) Kinetics As A Potential Surrogate Biomarker In Patients (Pts) With Hepatocellular Carcinoma (HCC) Treated With Atezolizumab (Atezo) + Bevacizumab (Bev)